Janić, M.; Janež, A.; Šabović, M.; El-Tanani, M.; Rangraze, I.; Rizzo, M.; Lunder, M.
Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial. J. Clin. Med. 2024, 13, 6860.
https://doi.org/10.3390/jcm13226860
AMA Style
Janić M, Janež A, Šabović M, El-Tanani M, Rangraze I, Rizzo M, Lunder M.
Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial. Journal of Clinical Medicine. 2024; 13(22):6860.
https://doi.org/10.3390/jcm13226860
Chicago/Turabian Style
Janić, Miodrag, Andrej Janež, Mišo Šabović, Mohamed El-Tanani, Imran Rangraze, Manfredi Rizzo, and Mojca Lunder.
2024. "Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial" Journal of Clinical Medicine 13, no. 22: 6860.
https://doi.org/10.3390/jcm13226860
APA Style
Janić, M., Janež, A., Šabović, M., El-Tanani, M., Rangraze, I., Rizzo, M., & Lunder, M.
(2024). Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial. Journal of Clinical Medicine, 13(22), 6860.
https://doi.org/10.3390/jcm13226860
